Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 09:00 ET | Source: Aptose Biosciences, Inc.

Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
September 10, 2025 07:03 ET | Source: Research and Markets

Chronic Myelomonocytic Leukemia Market Analysis and Forecast Report 2025-2035, with Profiles of AbbVie, GlaxoSmithKline, Incyte, Jazz Pharmaceuticals, Novartis, Stemline Therapeutics, and More

Dublin, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The "Chronic Myelomonocytic Leukemia Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035" report has...
December 12, 2024 10:15 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells
December 10, 2024 14:10 ET | Source: Remedy Plan Therapeutics

UPDATE - Remedy Plan Therapeutics Showcases Preclinical Data from First-In-Class NAMPT Inhibitor, RPT1G, Demonstrating Synergy with BCL-2 Family Inhibitors in AML at the 2024 ASH Annual Meeting

Remedy Plan Therapeutics Showcases at 2024 ASH Annual Meeting, Synergy Between RPT1G and Venetoclax
December 10, 2024 08:00 ET | Source: Remedy Plan Therapeutics

Remedy Plan Therapeutics Showcases Preclinical Data from First-In-Class NAMPT Inhibitor, RPT1G, Demonstrating Synergy with BCL-2 Family Inhibitors in AML at the 2024 ASH Annual Meeting

Remedy Plan Therapeutics Showcases at 2024 ASH Annual Meeting, Synergy Between RPT1G and Venetoclax
July 01, 2024 09:04 ET | Source: Research and Markets

Chronic Myelomonocytic Leukaemia Drug Pipeline Research 2024

Dublin, July 01, 2024 (GLOBE NEWSWIRE) -- The "Chronic Myelomonocytic Leukaemia - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Chronic...
June 20, 2024 05:58 ET | Source: Research and Markets

Innovative Developments in Acute Lymphocytic Leukemia (ALL) Treatments Global Pipeline Report 2024

Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Acute Lymphocytic Leukemia (ALL) - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.Global insights into the...
January 23, 2024 15:23 ET | Source: Research and Markets

Leukemia Therapeutics Market: Robust Growth Expected with Innovative CAR-T Treatments

Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The latest comprehensive research on...
October 30, 2023 09:15 ET | Source: Aptose Biosciences, Inc.

Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients
May 08, 2023 05:33 ET | Source: Research and Markets

Global Leukemia Therapeutics Market Report 2023: Rising Prevalence of Leukemia is Driving Growth

Dublin, May 08, 2023 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...